About: Vemurafenib     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz:8890 associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Vemurafenib
rdfs:subClassOf
Has_Target
Concept_In_Subset
Semantic_Type
  • Organic Chemical
  • Pharmacologic Substance
Preferred_Name
  • Vemurafenib
UMLS_CUI
  • C1832009
CAS_Registry
  • 918504-65-1
Accepted_Therapeutic_Use_For
  • Advanced Melanoma
FDA_UNII_Code
  • 207SMY3FQT
Contributing_Source
  • FDA
ALT_DEFINITION
  • A substance being studied in the treatment of cancer. BRAF (V600E) kinase is a mutated (changed) form of a cell protein called BRAF. It is found in several types of cancer, including melanoma (a type of skin cancer). Inhibiting this kinase may cause cancer cells to die. BRAF (V600E) kinase is a type of serine/threonine kinase inhibitor and a type of targeted therapy agent.NCI-GLOSS
PDQ_Open_Trial_Search_ID
  • 528954
PDQ_Closed_Trial_Search_ID
  • 528954
Chemical_Formula
  • C23H18ClF2N3O3S
Legacy_Concept_Name
  • PLX4032
CHEBI_ID
  • CHEBI:63637
FULL_SYN
  • VemurafenibPTNCI
  • RG7204PTNCI-GLOSSCDR0000670003
  • BRAF(V600E) Kinase Inhibitor RO5185426SYNCI
  • PLX4032PTNCI-GLOSSCDR0000670004
  • RG7204CNNCI
  • RG 7204CNNCI
  • PLX-4032CNNCI
  • 1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-SNNCI
  • ZelborafBRNCI
  • VEMURAFENIBPTFDA207SMY3FQT
  • RO 5185426CNNCI
  • BRAF (V600E) kinase inhibitor RO5185426PTNCI-GLOSSCDR0000670002
DEFINITION
  • An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.NCI
code
  • C64768
sameAs
is sameAs of
Faceted Search & Find service v1.16.121 as of Mar 31 2025


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3240 as of Mar 31 2025, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 13 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software